Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.eururo.2022.02.023
PubMed Identifier: 35397952
Publication URI: http://europepmc.org/abstract/MED/35397952
Type: Journal Article/Review
Parent Publication: European Urology
Issue: 1
ISSN: 0302-2838